FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial

PHASE3RecruitingINTERVENTIONAL

Enrollment

200

Participants

Timeline

Start Date

December 26, 2023

Primary Completion Date

July 26, 2025

Study Completion Date

December 26, 2026

Conditions

Hepatocellular Carcinoma

Interventions

PROCEDURE

Hepatic arterial infusion chemotherapy

administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries

DRUG

Lenvatinib

12 mg (or 8 mg) once daily (QD) oral dosing

DRUG

Toripalimab

240 mg iv.drip Q3W

DRUG

oxaliplatin , fluorouracil, and leucovorin

FOLFOX-HAIC

Trial Locations (1)

RECRUITING

Cancer Center Sun Yat-sen University, Guangzhou

All Listed Sponsors

lead

Sun Yat-sen University

OTHER